Inside Drug Development: Bimagrumab, mTOR, and the Science of Making Longevity Medicines
Physician-scientist Lloyd Klickstein walks through drug discovery from target selection to clinical trials, using bimagrumab and mTOR inhibition as case studies.
Summary
In this episode of The Peter Attia Drive, physician-scientist Lloyd Klickstein offers a rare insider account of how new drugs are developed, using bimagrumab — an antibody targeting myostatin and activin signaling — as a detailed case study. He traces the full arc from identifying sarcopenia as an unmet medical need, through antibody engineering, animal studies, toxicology, IND submission, and into human clinical trials. A pivotal discovery along the way was bimagrumab's unexpected ability to reduce fat mass and improve metabolic markers in type 2 diabetes, redirecting development toward obesity. The conversation also covers the BELIEVE trial combining bimagrumab with semaglutide, the economics and regulatory mechanics of drug development, selective mTORC1 inhibition as a geroprotective strategy, and Klickstein's current work on pharmacologic cancer prevention.
Detailed Summary
Understanding how longevity-relevant drugs actually reach patients is essential context for anyone tracking the field — yet few discussions open that black box with scientific rigor. This episode does exactly that, using bimagrumab as an extended case study to illuminate every stage of modern drug development.
Lloyd Klickstein, a physician-scientist with over two decades spanning academic medicine, translational research, and biotechnology, joins Peter Attia to explain how scientists choose a therapeutic target. Sarcopenia — the age-related loss of muscle mass and strength — was selected partly because of its enormous unmet need and partly because the myostatin and activin pathway offered a biologically tractable entry point. Klickstein explains why follistatin was considered and ultimately passed over, and how bimagrumab was engineered, screened, and refined from candidate antibodies into a clinical asset.
The episode walks through the less-glamorous but critical phases: animal proof-of-concept showing impressive muscle hypertrophy, toxicology studies, capital allocation decisions, GMP manufacturing requirements, and the regulatory logic behind IND submission. First-in-human study design, volunteer protection, phase 1 dosing, and pharmacodynamic endpoints are explained in practical terms.
Phase 2 trials revealed an unexpected finding: bimagrumab substantially reduced fat mass and improved glycemic control in people with type 2 diabetes, reorienting its development toward obesity treatment. This led to the BELIEVE trial, combining bimagrumab with semaglutide to evaluate additive or synergistic effects on body composition — a combination that addresses both the fat-loss and muscle-preservation challenges of GLP-1-based obesity therapy.
The conversation closes with selective mTORC1 inhibition as a geroprotective strategy, the methodological challenges of testing drugs against aging itself, and Klickstein's emerging pharmacologic approach to cancer prevention. The episode is an unusually transparent account of the science, economics, and regulatory gatekeeping that determine which longevity ideas ever reach a patient.
Key Findings
- Bimagrumab targets myostatin and activin signaling to increase muscle mass, with animal studies showing impressive hypertrophy.
- Phase 2 trials revealed bimagrumab unexpectedly reduces fat mass and improves glycemic control in type 2 diabetes.
- The BELIEVE trial combines bimagrumab with semaglutide to address both fat loss and muscle preservation in obesity treatment.
- Selective mTORC1 inhibition is discussed as a promising geroprotective strategy, though testing it against aging poses major trial design challenges.
- Identifying failures early in drug development is economically and scientifically critical — most candidate drugs fail in late, expensive stages.
Methodology
This is a long-form podcast episode featuring an expert interview, not a primary research study. Content is drawn from Klickstein's direct experience in drug development and from published clinical trial data on bimagrumab. No original experimental methodology is presented; the episode synthesizes regulatory, economic, and scientific information across multiple development phases.
Study Limitations
This is a podcast discussion, not a peer-reviewed publication, so claims cannot be independently verified through standard scientific review. The bimagrumab clinical trial data referenced are described qualitatively rather than quantitatively. Summary is based on show notes and episode description only, as the full transcript was not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: